Fosun Pharma Unit Wins Clinical Trial Approval for SRT-003-1 Diagnostic Drug

Stock News
昨天

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (600196.SH) announced that its controlling subsidiary, Chengdu Xingrui Jingxuan Biotechnology Co., Ltd., has received approval from the National Medical Products Administration to conduct clinical trials of [18F]F-SR031 injection, also known as SRT-003-1, for positron emission tomography (PET) imaging of fibroblast activation protein (FAP)-positive lesions in patients with solid tumors.

The subsidiary plans to initiate a Phase I clinical study of the drug in China once conditions permit.

SRT-003-1 is a radioactive in vivo diagnostic agent targeting fibroblast activation protein (FAP), intended primarily for PET imaging of FAP-positive lesions in solid tumor patients. FAP is a type II transmembrane serine protease belonging to the prolyl oligopeptidase family. It is barely expressed in normal tissues but is selectively overexpressed in cancer-associated fibroblasts (CAFs) of various epithelial tumors, including gastric cancer, esophageal cancer, lung cancer, colorectal cancer, and ovarian cancer. FAP inhibitors labeled with fluorine-18F can specifically bind to FAP on the surface of CAFs, causing FAP-overexpressing tumor lesions to show high uptake on PET imaging, thereby enabling tumor diagnosis, staging, and efficacy evaluation.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10